Xyntha®(antihemophilic factor [recombinant]) - Step Therapy - UnitedHealthcare Commercial Plansopen_in_new
UnitedHealthcare Step Therapy program requiring trial of preferred recombinant factor VIII products before coverage of Xyntha for Hemophilia A; includes approval criteria, duration, and administrative rules for commercial plans.
Program effective date set to 11/16/2025 and P&T approval dates updated through 9/2025.
Preferred agents list updated over time to add Advate and Recombinate (9/2020).
Physician attestation language was modified to 'prescriber attestation' (9/2023).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.